The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | The use of early PET responses to predict the risk of relapse after second-line axi-cel in LBCL
Andrea Kuhnl, MD, King’s College Hospital, London, UK, comments on the importance of early PET responses in predicting the risk of relapse after CAR T-cell therapy in LBCL patients. Dr Kuhnl highlights that an analysis of real-world data showed that the depth of response on a one-month PET scan after second-line axicabtagene ciloleucel (axi-cel) therapy was a significant predictor of early progression, and this information can be used to guide post–CAR-T management. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Around 50 to 60% of patients who undergo CAR T-cell therapy will progress eventually. And we have a growing number of post–CAR-T treatments available for these patients. So it’s really important to identify refractory patients relatively early before these patients become too unwell with high tumor burden disease progression. So in this regard we have looked into our second line axi-cel UK real-world cohort and have found that the depth of response on the one month PET scan after axi-cel is highly significant to predict the risk of early progression, so could potentially guide post-CAR-T therapies...
Around 50 to 60% of patients who undergo CAR T-cell therapy will progress eventually. And we have a growing number of post–CAR-T treatments available for these patients. So it’s really important to identify refractory patients relatively early before these patients become too unwell with high tumor burden disease progression. So in this regard we have looked into our second line axi-cel UK real-world cohort and have found that the depth of response on the one month PET scan after axi-cel is highly significant to predict the risk of early progression, so could potentially guide post-CAR-T therapies. So for example, a responding patient with still some residual activity on the one month scan has, according to our data, a 70% chance of progressing by month six, so we think should indeed be considered for additional therapy relatively early on.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consultancy: Kite Gilead, Roche, Abbvie, BMS; Honoraria: Kite Gilead, Astra Zeneca.
